Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

NCT ID: NCT05833282

Last Updated: 2023-04-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-07-01
• Study Completion Date: 2023-06-30

Brief Summary

Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

Detailed Description

INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

PRIMARY ENDPOINT

• The primary endpoint is 30-day mortality.

Conditions

Drug Resistance, Multiple, Bacterial

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

Exclusion Criteria

• Patient who is a minor, protected adult, or who refuses to participate.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tourcoing Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre Hospitalier DRON

Tourcoing, , France

Site Status: RECRUITING

Countries

France

Central Contacts

MEYBECK Angès, MD

Role: CONTACT

recherche@ch-tourcoing.fr

0320694238

Facility Contacts

MEYBECK Agnès, MD

Role: primary

recherche@ch-touroing.fr

0320694949

Other Identifiers

NRIPH_2023_01

Identifier Type: -

Identifier Source: org_study_id